RELMADA THERAPEUTICS, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that RELMADA THERAPEUTICS, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Aug 31, 2013 | $5.1K | Dec 16, 2013 |
| FY2013 | Aug 31, 2012 | $7.9K | Dec 16, 2013 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Aug 31, 2013 | $1.1K | Dec 16, 2013 |
| FY2013 | Aug 31, 2012 | $2.1K | Dec 16, 2013 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($57.39M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($79.98M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($98.79M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($157.04M) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | ($125.75M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($59.46M) | Mar 25, 2022 |
| FY2020 | Dec 31, 2019 | ($8.20M) | Mar 24, 2021 |
| FY2020 | Jun 30, 2019 | ($17.32M) | Mar 24, 2021 |
| FY2019 | Jun 30, 2018 | ($8.96M) | Sep 24, 2019 |
| FY2018 | Jun 30, 2017 | ($6.29M) | Sep 28, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($59.10M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($83.89M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($103.70M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($161.25M) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | ($125.70M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($60.84M) | Mar 25, 2022 |
| FY2020 | Dec 31, 2019 | ($8.27M) | Mar 24, 2021 |
| FY2020 | Jun 30, 2019 | ($12.73M) | Mar 24, 2021 |
| FY2019 | Jun 30, 2018 | ($6.92M) | Sep 24, 2019 |
| FY2018 | Jun 30, 2017 | ($7.22M) | Sep 28, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $26.88M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $46.18M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $54.81M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $113.32M | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | $90.62M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $35.97M | Mar 25, 2022 |
| FY2020 | Dec 31, 2019 | $3.51M | Mar 24, 2021 |
| FY2020 | Jun 30, 2019 | $7.02M | Mar 24, 2021 |
| FY2019 | Jun 30, 2018 | $2.94M | Sep 24, 2019 |
| FY2018 | Jun 30, 2017 | $1.29M | Sep 28, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($45.79M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($51.76M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($51.66M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($103.80M) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | ($91.87M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($27.81M) | Mar 25, 2022 |
| FY2020 | Dec 31, 2019 | ($6.41M) | Mar 24, 2021 |
| FY2020 | Jun 30, 2019 | ($10.50M) | Mar 24, 2021 |
| FY2019 | Jun 30, 2018 | ($6.00M) | Sep 24, 2019 |
| FY2018 | Jun 30, 2017 | ($6.47M) | Sep 28, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Aug 31, 2013 | ($1.8K) | Dec 16, 2013 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $94.00M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $45.82M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $97.55M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $152.91M | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | $223.33M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $118.19M | Mar 25, 2022 |
| FY2020 | Dec 31, 2019 | $117.14M | Mar 24, 2021 |
| FY2020 | Jun 30, 2019 | $10.22M | Mar 24, 2021 |
| FY2019 | Jun 30, 2018 | $3.05M | Sep 24, 2019 |
| FY2018 | Jun 30, 2017 | $2.84M | Sep 28, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.49M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $10.30M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $12.19M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $12.47M | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | $15.06M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $12.60M | Mar 25, 2022 |
| FY2020 | Dec 31, 2019 | $1.46M | Mar 24, 2021 |
| FY2020 | Jun 30, 2019 | $2.61M | Mar 24, 2021 |
| FY2019 | Jun 30, 2018 | $8.56M | Sep 24, 2019 |
| FY2018 | Jun 30, 2017 | $1.38M | Sep 28, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $86.51M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $35.52M | Mar 19, 2026 |
| FY2025 | Dec 31, 2023 | $85.36M | Mar 19, 2026 |
| FY2024 | Dec 31, 2022 | $140.44M | Mar 27, 2025 |
| FY2023 | Dec 31, 2021 | $208.26M | Mar 19, 2024 |
| FY2022 | Dec 31, 2020 | $105.58M | Mar 23, 2023 |
| FY2021 | Dec 31, 2019 | $115.68M | Mar 25, 2022 |
| FY2020 | Jun 30, 2019 | $7.61M | Mar 24, 2021 |
| FY2020 | Jun 30, 2018 | ($5.51M) | Mar 24, 2021 |
| FY2019 | Jun 30, 2017 | $1.46M | Sep 24, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($698.27M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($640.88M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($560.90M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($462.11M) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | ($305.07M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($179.32M) | Mar 25, 2022 |
| FY2020 | Dec 31, 2019 | ($119.86M) | Mar 24, 2021 |
| FY2020 | Jun 30, 2019 | ($111.66M) | Mar 24, 2021 |
| FY2019 | Jun 30, 2018 | ($94.34M) | Sep 24, 2019 |
| FY2018 | Jun 30, 2017 | ($85.38M) | Sep 28, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.50M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $3.86M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $4.09M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $5.40M | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | $44.44M | Mar 23, 2023 |
| FY2020 | Dec 31, 2020 | $2.50M | Mar 24, 2021 |
| FY2020 | Dec 31, 2019 | $36.28M | Mar 24, 2021 |
| FY2020 | Jun 30, 2019 | $9.22M | Mar 24, 2021 |
| FY2020 | Dec 31, 2018 | $2.43M | Mar 24, 2021 |
| FY2020 | Jun 30, 2018 | $2.24M | Mar 24, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | (3) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | (5) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | (7) | Mar 23, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | (3) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | (5) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | (7) | Mar 23, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 73.33M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | 30.17M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | 30.10M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | 30.10M | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | 27.74M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | 16.33M | Mar 25, 2022 |
| FY2020 | Dec 31, 2019 | 14.46M | Mar 24, 2021 |
| FY2020 | Jun 30, 2019 | 9.74M | Mar 24, 2021 |
| FY2019 | Jun 30, 2018 | 12.55M | Sep 24, 2019 |
| FY2018 | Jun 30, 2017 | 12.53M | Sep 28, 2018 |